A Trial to Learn How BAY1817080 Moves Into, Through and Out of the Body and How Safe it is in Healthy Chinese Men

NCT04802343 | Completed Phase 1

• 1 other identifier: 21009
• Study Type: interventional
• Target: 39
• Locations: 1 country
• Sites: 1

Brief Summary

Researchers are looking for a better way to treat chronic cough. Before patients with medical conditions can join clinical trials, researchers do trials in healthy participants first to understand how the body acts on the new treatment and learn how safe it is. In this trial, the researchers will study how much of the trial drug, BAY1817080, gets into the blood in a small number of participants. The trial will include about 39 healthy Chinese male who are aged 18 to 45. For this trial participants will be divided in 3 groups. Groups 1 and 2 will take either dose 1 or dose 2 of BAY1817080 or placebo 1 time. Participants of groups 3 will take dose 3 of BAY1817080 or placebo one time at the first day and continue to take dose 3 of BAY1817080 twice a day from day 7 to day 16 of the trial. On day 17 they will take only one dose 3 of BAY1817080. All participants will take BAY1817080 or a placebo as a tablet by mouth. For this trial, the participants in Groups 1 and 2 will stay at the trial site for up to 10 days. The participants in Group 3 will stay at the trial site for up to 26 days. The trial will last up to 4 weeks for the participants in Groups 1 and 2, and 6 weeks for the participants in Group 3. During the trial, the doctors will take blood and urine samples and check the participants blood pressure, pulse rate and electrocardiogram (ECG). The participants will answer questions about how they are feeling to check their general wellbeing.

Conditions

Healthy Volunteers

Keywords

Pharmacokinetics (PK)

Outcome Measures

Primary Outcomes (6)

• Cmax of BAY1817080 dose 1 and dose 2 (Day 1)

  Cmax: maximum observed drug concentration in measured matrix after single dose administration

  Pre-dose on Day 1 to 216 hours post-dose

• Cmax of BAY1817080 dose 3 (Day 1)

  Cmax: maximum observed drug concentration in measured matrix after single dose administration

  Pre-dose on Day 1 to 144 hours post-dose

• AUC of BAY1817080 dose 1 and dose 2 (Day 1)

  AUC: area under the concentration vs. time curve

  Pre-dose on Day 1 to 216 hours post-dose

• AUC of BAY1817080 dose 3 (Day 1)

  AUC: area under the concentration vs. time curve

  Pre-dose on Day 1 to 144 hours post-dose

• Cmax,md of BAY1817080 in dose 3 cohort (Day 17)

  Cmax,md: maximum observed drug concentration in measured matrix after multiple dose administration during a dosage interval, directly taken from analytical data

  Pre-dose on Day 17 to 12 hours post-dose

• AUCτ,md of BAY1817080 in dose 3 cohort (Day 17)

  AUCτ,md: the area under the concentration-time curve in the dosing interval after multiple doses

  Pre-dose on Day 17 to 12 hours post-dose

Secondary Outcomes (1)

• Number of participants with treatment emergent adverse events (TEAEs) with intensity

  From the first dose of study intervention up to the follow-up visit (up to 30 days)

Study Arms (2)

BAY1817080 dose escalation

EXPERIMENTAL

Healthy male subjects will receive BAY1817080 dose 1 and dose 2 as a single oral dose and BAY1817080 dose 3 as a single oral dose on Day 1 and twice daily (BID) from Day 7 to Day 16 followed by a last dose in the morning of Day 17.

Drug: BAY1817080

Placebo

PLACEBO COMPARATOR

Healthy male subjects will received corresponding placebo.

Drug: Placebo

Interventions

BAY1817080 DRUG

Oral, tablet.

BAY1817080 dose escalation

Placebo DRUG

Oral, tablet.

Placebo

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Participants who are overtly healthy according to complete medical history, including the physical examination, vital signs (blood pressure, pulse rate), 12-Lead electrocardiogram (ECG), and clinical laboratory tests
• Race: Chinese
• Age: 18 to 45 years (inclusive) of age
• Weight: Body mass index (BMI): ≥ 18.0 and \<= 27.9 kg/m²
• Male participants
• Subjects who agree to use adequate contraception when sexually active during the study period and for 90 days after receiving the investigational medicinal product and not to act as sperm donor for 90 days after dosing.

You may not qualify if:

• Medical and Surgical History
• Any findings from the medical examination (including medical history, physical examination, vital signs, laboratory tests and ECG) deviating from normal and deemed by the investigator to be of clinical relevance
• Medical history of hypogeusia/dysgeusia or dysfunction in the ability to taste
• Any known presence or history of severe allergies, non-allergic drug reactions, or multiple drug allergies
• Known or suspected malignant tumors or carcinoma in situ
• Known liver disease: existing acute or chronic progressive liver disease, e.g. disturbance of bilirubin excretion (Dubin-Johnson and Rotor syndromes); disturbances of bile secretion and flow (cholestasis); presence or history of liver tumors (benign or malignant). (Note: According to this criterion, there must have been an interval of at least 6 months between the subsidence of any viral hepatitis \[normalization of liver parameters\] and the screening visit.)
• Any known relevant kidney disease (e.g. glomerulonephritis) or any renal injury associated with multisystem diseases/disorders (e.g. systemic lupus erythematosus, diabetic nephropathy)
• Known metabolic disorders (e.g. diabetes mellitus, severe hypertriglyceridemia)
• Known cardiovascular disorders requiring treatment
• Migraine with neurological symptoms (complicated migraine)
• Incompletely cured pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination and effects of the study drugs will not be normal
• Known hypersensitivity to the study interventions including components of the preparation Medication, drug use and special behavioral patterns
• Regular use of therapeutic or recreational drugs, e.g. carnitine products, anabolics, high-dose vitamins
• Intake of drugs with a long half-life (\>24 hours) within a timeframe of less than 5 half-lives before study drug administration
• Use of any systemic or topically active drug(s) that might influence the results of the study within the 14 days before study intervention administration or during the study until follow-up. (Note: This includes drugs that might affect the PK of BAY 1817080, e.g. laxatives, loperamide, metoclopramide, antacids, H2-receptor antagonists, cytochrome P450 \[CYP\] 3A4 inducers, strong CYP3A4 inhibitors).

Sponsors & Collaborators

• Bayer: lead

Study Sites (1)

Zhongshan Hospital, Fudan University

Shanghai, 200032, China

Location

Related Publications (1)

• Li X, Haranaka M, Li H, Liu P, Chen H, Klein S, Reif S, Francke K, Friedrich C, Okumura K. P2X3 Receptor Antagonist Eliapixant in Phase I Clinical Trials: Safety and Inter-ethnic Comparison of Pharmacokinetics in Healthy Chinese and Japanese Participants. Clin Pharmacokinet. 2024 Jun;63(6):901-915. doi: 10.1007/s40262-024-01387-y. Epub 2024 Jun 21.

  PMID: 38907175 DERIVED

Related Links

• Click here to find information for studies related to Bayer products. To find this study enter the ClinicalTrials.gov identifier (NCT) number or Bayer Study Identifier (ID) in the search field.

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: OTHER
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 15, 2021
• First Posted: March 17, 2021
• Study Start: April 2, 2021
• Primary Completion: July 19, 2021
• Study Completion: October 29, 2021
• Last Updated: October 19, 2022

Record last verified: 2022-10

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)